BrainChild Bio targets deadly pediatric brain cancer with $116M series A

BCB-276Positive

AI Analysis

Summary

BrainChild Bio raised $116M in Series A funding to advance BCB-276, its lead asset in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal pediatric brain tumor affecting approximately 300 children annually in the U.S.

Clinical Trial Data

Phase

pivotal

Importance:6/10

Sentiment:

0.60

pediatric oncologyrare diseasebrain cancerSeries A fundingdiffuse intrinsic pontine glioma

Related Companies

$BNN.DE

Read the original article

Published by BioSpace on September 8, 2026 11:01 AM

Read Original